Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614576 | 1.00 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1MAPTLCK | |
| SCHEMBL753224 | 0.83 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1MAPTHPGD | |
| SCHEMBL753810 | 0.82 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1MAPTMEN1 | |
| SCHEMBL15441436 | 0.80 | NPSR1 (0.43) | MAPK1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL31723056 | 0.80 | GABRG2 (0.57) | MAPK1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL347328 | 0.80 | CYP1A2 (0.51) | MAPK1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL8258906 | 0.80 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1MAPTLCK | |
| SCHEMBL22031779 | 0.79 | MAPK1 (0.62) | MAPK1KDM4EL3MBTL1MAPTLCK | |
| SCHEMBL29049994 | 0.79 | MAPK1 (0.41) | MAPK1KDM4EL3MBTL1GRM5NPC1 | |
| SCHEMBL29514365 | 0.79 | MAPK1 (0.41) | MAPK1KDM4EL3MBTL1GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115349524-A | Herbicidal mixtures | 孟山都技术有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4746972-A1 | DEUTERATED PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094947-A | PARP1 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122094958-A | PARP1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1456175-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1307444-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010154-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| US-4923504-A | 2-(2-Imidazolin-2-yl)pyridines and quinolines, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4798619-A | 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents | AMERICAN CYANAMID CO. (US) | 1989-01-17 | — | — | US | disclosed |
| US-4638068-A | 2-(2-imidazolin-2-yl)-pyridines and quinolines, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | MAPK1 347/4885KDM4E 892/4885L3MBTL1 245/4885 |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | MAPK1 2144/4885KDM4E 2201/4885L3MBTL1 967/4885 |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | MAPK1 2282/4885KDM4E 442/4885L3MBTL1 1370/4885 |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | F11, SERPINC1, TFPI | MAPK1 821/4885KDM4E 2131/4885L3MBTL1 4241/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | MAPK1 3753/4885KDM4E 4185/4885L3MBTL1 23/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | MAPK1 601/4885KDM4E 530/4885L3MBTL1 1491/4885 |
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | MAPK1 1107/4885KDM4E 2216/4885L3MBTL1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.